New opportunities for the management and therapy of hepatitis C in correctional settings.
Where this comes from
- Record sourced from PubMed, PMID 20007626.
- Also identified by DOI 10.2105/AJPH.2008.147629 and PMC identifier 2791263.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hepatitis C in prison populations is now a major public health problem, and large numbers of correctional facilities have no comprehensive management program, often because of formidable projected costs and tightening budget constraints. The North Dakota Department of Corrections and Rehabilitation has operated a management and therapy program since 2002 using consensus interferon and ribavirin with 45% cost savings. The program has provided excellent sustained viral responses: 54.2% for genotype 1 hepatitis C, 75% for genotypes 2 and 3, and 63.6% overall.
Medical subject headings
- Antiviral Agents
- Hepatitis C
- Interferon Type I
- Prisons
- Ribavirin